Sintesi Research acts as a partner for the whole spectrum of clinical investigations, with ad-hoc teams led by experienced Clinical Project Managers.
Sales, strategic initiatives, business partnerships, market development, business expansion, and marketing are all included in our activities.
Sintesi Research coordinates private investors working alongside VC in Medical companies across Europe, Israel and US.
Paolo is the founder of Sintesi Research Srl and since 2005 he is responsible for the overall management of the Company and Company’s operations including research and development.
Paolo brings more than 30 years of experience in the pharmaceutical industry and International CROs.
PAOLO DE SIMONI
Chief Executive Officer
Rachel has a vast experience of Business development and Marketing on a global level. She is CFO since 2013 and COO since 2018 at Sintesi Research Israel.
Rachel is responsible for designing and implementing business operations as well as establishing policies that promote company culture and vision.
Chief Operating Officer and
Alessandra is a business development manager with 15 years of experience in researching solutions and new business opportunities worldwide.
She joined Sintesi Research in 2021 as responsible for creating strategic marketing plans and contacting potential clients in order to get access to new collaborations.
She collaborates with cross-functional teams to improve customer service experience and needs.
Focused on building strong and dedicated client relationship and partnership, built on trust.
Andrea is responsible for IT solutions at Sintesi Research S.r.l. since 2016. He brings more than 20 years of IT experience, covering system management and maintenance, b2b assistance, retail assistance, network management and system building.
Information Technology Manager
“Every client is a “new” client for us. We execute every project with the utmost attention to details, and uncompromised focus on quality which has earned us the confidence and trust of national and international biotechnology and pharmaceuticals companies.”
Paolo De Simoni